TD Cowen Downgrades Harpoon Therapeutics to Market Perform
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Tara Bancroft has downgraded Harpoon Therapeutics (NASDAQ:HARP) from Outperform to Market Perform, indicating a change in the stock's expected performance.

January 16, 2024 | 7:49 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Harpoon Therapeutics was downgraded by TD Cowen from Outperform to Market Perform, which may influence investors' perception of the stock's future performance.
Downgrades by analysts can lead to a negative short-term reaction in the stock market as they suggest a less optimistic outlook on the company's performance. Given that this is a direct downgrade from Outperform to Market Perform, it implies a significant change in expectations, which is likely to be taken seriously by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100